✦ LIBER ✦

Peculiar antibody reactivity to human connexin 37 and its microbial mimics in patients with Crohn's disease

✍ Scribed by Andreas Koutsoumpas; Dimitrios Polymeros; Zacharias Tsiamoulos; Daniel Smyk; George Karamanolis; Konstantinos Triantafyllou; E.I. Rigopoulou; Alastair Forbes; Diego Vergani; Dimitrios P. Bogdanos; Spiros D. Ladas

Book ID: 119223276
Publisher: Oxford University Press
Year: 2011
Tongue: English
Weight: 561 KB
Volume: 5
Category: Article
ISSN: 1873-9946
DOI: 10.1016/j.crohns.2010.10.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Increased antibody response to microbial

Increased antibody response to microbial antigens in patients with Crohn's disease and their unaffected first-degree relatives

✍ Michielan, Andrea; Basso, Daniela; Martinato, Matteo; Pathak, Surajit; Banerjee, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 474 KB

Clinical significance of anti-Saccharomy

Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn's disease and its relationship to the disease clinical course

✍ B.C. Kim; S. Park; J. Han; J.H. Kim; T.I. Kim; W.H. Kim 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 204 KB

T1132 Pharmacokinetics and Exposure-Resp

T1132 Pharmacokinetics and Exposure-Response Relationship of Ustekinumab, a Human Monoclonal Antibody to Interleukin 12/23, in Patients with Moderate-to-Severe Crohn's Disease

✍ Fasanmade, Adedigbo A.; Adedokun, Omoniyi J.; Johanns, Jewel R.; Zhou, Honghui; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

493 Safety Profile and Signal of Efficac

493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

✍ Christien J. van der Woude; Pieter C. Stokkers; Ad A. van Bodegraven; Gert A. Va 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 87 KB